Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.

ABSTRACT:

Background

Sublingual immunotherapy (SLIT) with peanut changes clinical and immune responses in most peanut-allergic individuals, but the response is highly variable.

Objective

We sought to examine the component-specific effects of peanut SLIT and determine whether peanut component testing could predict the outcome of a double-blind, placebo-controlled food challenge (DBPCFC) after 12 months of peanut SLIT.

Methods

We included 33 subjects who underwent peanut SLIT with a DBPCFC of 2500 mg of peanut protein performed after 12 months of therapy. Plasma samples from baseline and after 12 months of peanut SLIT were assayed using ImmunoCAP for IgE and IgG4 against whole peanut, Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9.

Results

Following 12 months of SLIT, 10

SUBMITTER: Burk CM 

PROVIDER: S-EPMC4732904 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature